Phase III study of gefitinib versus erlotinib in patients with previously treated lung adenocarcinoma.
Phase of Trial: Phase III
Latest Information Update: 12 May 2016
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 28 Mar 2016 Results published in the Journal of Clinical Oncology.
- 17 Oct 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 31 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.